tbuckley/cabot-search huggingface dataset:
THU0715-HPR Stratified exercise therapy by physical therapists in primary care is feasible in patients with knee osteoarthritis
Authors: J. Knoop, M. van der Leeden, M. van der Esch, M. de Rooij, W.F. Peter, K.L. Bennell, M.P. Steultjens, A. Hakkinen, L.D. Roorda, W.F. Lems, J. Dekker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There is strong evidence that exercise therapy is effective in reducing pain and activity limitations in knee osteoarthritis (OA), but effect sizes are low to moderate. Stratified exercise therapy tailored to clinically relevant subgroups of patients is expected to optimise treatment effects in a cost-effective manner. <h3>Objectives</h3> This study aimed to explore the feasibility of a newly developed model of stratified exercise therapy in primary care. <h3>Methods</h3> A mixed method design was used, consisting of an uncontrolled pretest-posttest design and a process evaluation. Eligible patients visiting a participating primary care physical therapist (PT) were included. Based on our model, participants were allocated to the 'high muscle strength subgroup', 'low muscle strength subgroup', 'obesity subgroup' or 'depression subgroup', and received subgroup-specific, protocolised, 4 month exercise therapy. Feasibility of stratified exercise therapy according to this model was evaluated by a process evaluation (process documentation, semi-structured interviews and focus group meeting) and outcome (physical functioning (KOOS-ADL) and knee pain (NRS), assessed at baseline and 4 months follow-up). <h3>Results</h3> We included 50 patients, of which 3 patients dropped out. The process evaluation suggests that our model is feasible for patients and PTs, with some adaptations for further optimisation. We found clinically relevant improvements on physical functioning (p&lt;0.001; 20%) and knee pain (p&lt;0.001; 37%) for the total group. PTs provided on average 10 sessions, ranging from 2 to 24. The average number of sessions was 6 for the 'high muscle strength subgroup', 12 for the 'low muscle strength subgroup', 13 for the 'obesity subgroup' and 16 for the 'depression subgroup'. <h3>Conclusions</h3> Our model of stratified exercise therapy is feasible in primary care. Minor adaptations could further optimise the feasibility. Future research should determine the (cost-)effectiveness of this model, compared to usual, non-stratified exercise therapy. <h3>Disclosure of Interest</h3> None declared
Abstract 16511: Gender Differences in the Diagnostic Performance of a Machine Learning Based CT Angiography Derived FFR Algorithm Insights From the MACHINE Registry
Authors: Stefan Baumann, Matthias Renker, Christian Tesche, Moritz H Albrecht, Adriaan Coenen, Koen Nieman, Jakob De Geer, Anders Persson, Mariusz Kruk, Cezary Kepka, Dong Hyun Yang, Christel Weiss, Ibrahim Akin, Martin Borggrefe, U J Schoepf
Journal: Circulation (2017)

Introduction: CT derived fractional flow reserve (cFFR) is an approach using computational fluid-dynamic models and offers improved diagnostic accuracy in detecting haemodynamically relevant lesion...
IDWeek Fosters Innovation in Infectious Disease Care
Authors: Dara Grennan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism
Authors: Lauren Marsh Shevell, Eun-Ju Lee, Rahul Dhodapkar, Daniel Dykas, Andreea Popa, Deqiong Ma, Noffar Bar, Audrey Baluha, Adrienne J. Burns, Cassius Ilya Ochoa Chaar, Anne Dupont, Sean Gu, Stephanie Halene, Randy Luciano, Rebecca Marien, Natalia Neparidze, Terri L Parker, Xiaopan Yao, Rodney M. Camire, Eduard Ebberink, Pablo Garcia de Frutos, Kavitha Gnanasambandan, Peter P. Sayeski, James A. Huntington, Steven R. Lentz, Koen Mertens, Christopher Parish, Ray Rezaie, Jean M. Connors, Andrew Leavitt, Allen Bale, Alfred Ian Lee
Journal: Blood (2018)
Infographic. Unravelling confusion in sports medicine and science practice: a systematic approach
Authors: Clare L Ardern, Gregory Dupont, Franco M Impellizzeri, Gary O’Driscoll, Guus Reurink, Colin Lewin, Alan McCall
Journal: British Journal of Sports Medicine (2019)

One of the challenges of working in professional sport is the constant pressure to be innovative, to adopt new strategies, techniques and technologies to gain that all important competitive advantage. Players, managers and chief executive officers feel the pressure to perform and win matches—often this manifests as a perception of needing to accumulate all those marginal gains possible and fear of missing out, that is, another team has a cryotherapy chamber, so we should too, even if it may not be effective. The medical and performance team feel pressure to provide these so-called ‘one-percenters’ that players and managers and even the Board can obsessively chase. In this process, practitioners often come up against charismatic forces hawking the next silver bullet, magic potion or black box that will claim to win games, improve performance, enhance recovery and predict injury or talent. There is also the fact that …
Abstract MP073: Sleep Patterns and Depression in a Diverse Sample of Women from the AHA Go Red for Women Strategically Focused Research Network (SFRN)
Authors: Brooke Aggarwal, Ming Liao
Journal: Circulation (2017)

Background: Depression has been linked to increased risk of cardiovascular disease (CVD) through biological mechanisms and altered lifestyle behaviors, possibly including short and/or long sleep duration. However the relation between specific sleep components and depressive symptoms, and interaction by race/ethnicity has not been fully defined. The purpose of this study was to determine if sleep patterns including short sleep duration, poor sleep quality, and insomnia were associated with depressive symptoms in a free-living ethnically diverse population of adult women, and if they varied by racial/ethnic status. Methods: English or Spanish speaking females between the ages of 20-79 y, participating in an observational cohort study as part of the American Heart Association Go Red for Women SFRN, were included (n=50, 56% (28 of 50) non-white, mean age = 41 ±18y). Sleep patterns were assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated instrument used to measure the quality and duration of sleep in adults. Presence of insomnia was measured using the Insomnia Severity Index (ISI). Depressive symptoms were assessed using the Beck Depression Inventory (BDI-II). Linear and logistic regression models were used to evaluate cross-sectional associations between sleep patterns and depression overall, and by race/ethnicity. Results: Overall, nearly one-fifth of participants had depressive symptoms (BDI II score ≤13), 18% (9 of 50) had short sleep duration (&lt;6 hours per night), 38% (19 of 50) had poor quality sleep (PSQI score ≥5), and 40% (20 of 50) had some level of insomnia (ISI score ≥8). Mean BDI-II scores among women who slept &lt;6 versus ≥6 hours were significantly greater (16 versus 5, p=.0003). Higher depression scores were associated with shorter sleep duration (p=.001), poorer sleep quality (p=.03), and higher insomnia severity (p&lt;.0001) overall. There was no association between depression and long sleep (≥8 hours). When stratified by race/ethnicity, depression was significantly associated with poor sleep quality among minority women in multivariable models adjusted for demographic confounders (OR=1.42, 95% CI=1.03-1.95), but not among non-Hispanic white women. Depression was also significantly associated with insomnia severity (p&lt;.001), and sleep duration (p=.03) among minority women only, in multivariable adjusted models stratified by race/ethnicity. Conclusions: In this diverse sample of women, sleep problems were highly prevalent. Poor sleep quality, insomnia, and short sleep duration (but not long sleep) were associated with greater depressive symptoms among minority women but not whites. These preliminary data suggest that minority women with short sleep duration may be at heightened CVD risk from depression. Future research should determine if interventions designed to improve sleep result in decreased depressive symptoms and reduced CVD risk.
Abstract 16616: Echocardiography Reveals Biventricular Abnormalities in Presymptomatic Phospholamban p.Arg14del Mutation Carriers
Authors: Wouter P te Rijdt, Yoran M Hummel, J. Peter van Tintelen, Rudolf A de Boer, Maarten P van den Berg
Journal: Circulation (2014)

Introduction: Echocardiographic myocardial deformation imaging is an emerging tool for assessing cardiac function and identifying preclinical cardiomyopathies. A large subset of our patients diagnosed with dilated cardiomyopathy (DCM) or arrhythmogenic right ventricular cardiomyopathy (ARVC) carry the pathogenic phospholamban (PLN) c.40_42delAGA (p.Arg14del) founder mutation. The natural course of these mutation carriers is characterized by a presymptomatic phase of variable length, after which many carriers progress to overt disease, manifesting as DCM and/or ARVC. Objective: To identify subclinical structural and functional cardiac abnormalities in presymptomatic carriers of an identical PLN p.Arg14del mutation using echocardiography including state-of-the-art tissue deformation imaging techniques. Methods: Twenty-eight presymptomatic PLN p.Arg14del mutation carriers (46% males; mean [±SD] age 33±11 years), identified by genetic cascade screening, and 28 healthy matched control subjects were included in this cross-sectional study. Both groups underwent comprehensive transthoracic echocardiography including LV and RV myocardial two-dimensional strain measurements. Global LV early diastolic tissue velocity (Global e’) and global longitudinal systolic strain (GLSS) were assessed from 12 LV segments and from 3 RV segments. Results: In the mutation carrier group, LV ejection fraction was preserved (59.0±5.2 vs. 58.8±5.3 (%), P=0.788). However, LV mass index was reduced (58.4±13.9 vs. 71.5±15.6 (g/m^2), P=0.002) and we also observed loss of diastolic function (LV early diastolic inflow 0.79±0.15 vs. 0.95±0.18 (m/sec), P=0.001; LV late diastolic inflow 0.52±0.13 vs. 0.60±0.13 (m/sec), P=0.031; Global e’ 6.7±1.3 vs. 7.4±1.2 (cm/s), P=0.081). In addition, RV GLSS was lower in mutation carriers compared with controls (25.4±4.6 vs. 31.4±4.9 (cm/s), P&lt;0.001). Conclusions: Presymptomatic PLN p.Arg14del mutation carriers already showed slight but significant structural remodeling (reduced LV mass) as well as loss of LV diastolic function and RV systolic function. These findings support the concept of biventricular cardiomyopathy.
FRI0632 Impact of a tight control multidisciplinary rheumatology program on the quality of life of patients with autoinmune diseases in colombia
Authors: R. Pineda-Tamayo, M.-A. Alzate, D. Hernandez-Parra, D. Echeverry, P. Ortiz-Salazar, A. Rojas-Villarraga
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Autoimmune diseases are chronic inflammatory pathologies of complex etiology and variable clinical expression that usually affect young individuals, generating chronical pain and altering their functionality. Therefore, one of the mainstays of the treatment is to improve the quality of life (QoL) of these patients <h3>Objectives:</h3> To determine the impact of a tight control multidisciplinary rheumatologyprogram in the QoL of patients with rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) and seronegative spondyloarthropathies (SpA). <h3>Methods:</h3> A analytical quasi-experimental study was conducted were 3812 patients with RA, 590 patients with SLE and 605 patients with SpA were included and followed between February 2015 and December 2016. Two separated measurements of QoL were developed through the EuroQol Five Dimensions Questionnaire (EQ-5D) by time trade-off (TTO) valuation technique and the visual analogue scale valuation technique (EQ-VAS). Sociodemographic characteristics were analyzed with univariate statistic. The impact on QoL was determined by McNemar test and repeated measures analysis of variance (rANOVA) <h3>Results:</h3> The most affected dimensions of the EQ-5D were pain/discomfort and anxiety/depression, while the least affected was self-care. When comparing each dimension before and after the entry to the tight control program, a significant increase in the proportion of patients that perceive level 1 for each aspect evaluated was found. In addition, significant improvement was found in the global EQ-VAS (table 1) <h3>Conclusions:</h3> The tight control multidisciplinary rheumatology program is an efficient strategy to improve the QoL and the health perception of patients with chronic autoimmune diseases which impacts on the functionality, performance of everyday activities and productivity <h3>Reference</h3> 1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine2015;278(2015):369–395. doi:10.1111/joim.12395 <h3>Disclosure of Interest:</h3> None declared
FRI0278 Alterations in memory and visio-spatial learning in a pristane-induced lupus balb/c mice
Authors: J. Luciano Jaramillo, F. Sandoval Garcia, E.A. Martinez Garcia, M. Vazquez Del Mercado, B.T. Martin Marquez
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Neuropsychiatric lupus is a condition that occurs in 30%–40% of systemic lupus erythematosus (SLE) patients and is associated with the presence of autoantibodies in central nervous system (CNS). The pristane-induced lupus in BALB/c mice is an experimental model that presents clinical and immunological similarities to SLE pathogenesis and it can be proposed as model to analyse affectations in visio-spatial learning and memory. <h3>Objectives</h3> To evaluate short and long term visio-spatial learning and memory in Balb/c pristane-induced lupus using Barnes maze test. <h3>Methods</h3> Fourteen female Balb/c mice were studied: 4 controls (single intraperitoneal injection of 0.5 mL NaCl 0.9%), 5 treated with pristane (single intraperitoneal injection of 0.5 mL pristane) and 5 treated with pristane plus lipopolysaccharide (LPS) 3 mg/kg 4 months post-administration of pristane. Short and long term visio-spatial learning and memory was evaluated in all groups at 7 weeks after the administration of LPS using Barnes maze test. The test consists of 3 phases: adaptation phase, acquisition phase and test phase. The short-term memory was evaluated during the acquisition phase (4 tests per day, D1-D4) and the long-term memory was evaluated 48 hour after the last test of the acquisition phase. Primary and total errors, primary and total latencies were analysed. The results are shown as a mean ±SD. Kruscal-Wallis and Mann-Whitney U test was used for statistical analysis. <h3>Results</h3> All mice treated with pristane showed higher latencies to find the target hole in Barnes maze compared with controls during the short-term memory test (STP, D1-D4). In the long-term memory test (LTP) the highest latency in seconds (s) was observed in the pristane plus LPS group (64.6±59.1 s) followed by the pristane group (62.4±69.6 s) in comparation control group (7±3.6 s). <h3>Conclusions</h3> The increased latencies in the groups pristane plus LPS and pristane with respect to controls suggests that the autoantibodies produced in this model could be involved in alterations of the CNS, modifying the learning and memory processes. These results also suggest that pristane may have the potential to alter the permeability of the blood-brain barrier by itself. However, more experimental studies are needed to confirm the results obtained in this study. <h3>Disclosure of Interest</h3> None declared
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
Authors: Filippo Rossignoli, Carlotta Spano, Giulia Grisendi, Elisabetta Manuela Foppiani, Giulia Golinelli, Ilenia Mastrolia, Marco Bestagno, Olivia Candini, Tiziana Petrachi, Alessandra Recchia, Francesca Miselli, Giulia Rovesti, Giulia Orsi, Elena Veronesi, Gregorio Medici, Benedetta Petocchi, Massimo Pinelli, Edwin M Horwitz, Pierfranco Conte, Massimo Dominici
Journal: Theranostics (2019)

Pancreatic cancer is the fourth leading cause of cancer death in western countries with more than 100,000 new cases per year in Europe and a mortality rate higher than 90%. In this scenario, advanced therapies based on gene therapies are emerging, thanks to a better understanding of tumour architecture and cancer cell alterations. We have demonstrated the efficacy of an innovative approach for pancreatic cancer based on mesenchymal stromal cells (MSC) genetically engineered to produce TNF-related Apoptosis Inducing Ligand (TRAIL). Here we investigated the combination of this MSC-based approach with the administration of a paclitaxel (PTX)-based chemotherapy to improve the potential of the treatment, also accounting for a possible resistance onset. Methods: Starting from the BXPC3 cell line, we generated and profiled a TRAIL-resistant model of pancreatic cancer, testing the impact of the combined treatment in vitro with specific cytotoxicity and metabolic assays. We then challenged the rationale in a subcutaneous mouse model of pancreatic cancer, assessing its effect on tumour size accounting stromal and parenchymal organization. Results: PTX was able to restore pancreatic cancer sensitivity to MSC-delivered TRAIL by reverting its pro-survival gene expression profile. The two compounds cooperate both in vitro and in vivo and the combined treatment resulted in an improved cytotoxicity on tumour cells. Conclusion: In summary, this study uncovers the potential of a combinatory approach between MSC-delivered TRAIL and PTX, supporting the combination of cell-based products and conventional chemotherapeutics as a tool to improve the efficacy of the treatments, also addressing possible mechanisms of resistance.
SP0010 Fibroblast-matrix-vessel: the unhappy triad
Authors: C.P. Denton
Journal: Annals of the Rheumatic Diseases (2018)

Systemic sclerosis (SSc) is a complex multisystem disease that links autoimmunity, inflammation, vascular damage to development of fibrosis or scarring in target organs. The pathogenesis of the disease involves reciprocal interaction between the immunological, vascular and mesenchymal compartments and involves processes that are central to connective tissue growth and repair. However in the context of SSc this process is dysfunctional in that the amount of tissue damage is excessive or the repair process is dysregulated. Thus it seems likely that perturbation of the cross talk between cells and pathways that regulate the cell types involved are important in pathogenesis and represent appropriate targets for therapeutic intervention. It is likely that some emerging therapies can attenuate the pathogenesis of SSc by acting on multiple cell type sand this is perhaps especially relevant to an approach such as autologous haematopoietic stem cell transplant. However it is likely that individual pathways or mediators can be modified in a less extreme manner and have benefit as potential disease modifying therapy. A number of key mediators and pathways are emerging including IL6, TGFbeta and intracellular pathways linked to nuclear hormone receptors. These are being targeted experimentally. Another strategy for treatment would be targeting the initiating cells such as monocytes, especially those with a profibrotic phenotype, or the effector cells in fibrosis such as myofibroblasts. Evidence supporting these strategies is emerging and it is likely that restoration of a more balanced interaction between vessels, extracellular matrix and fibroblasts would underpin effective therapies for the fibrotic and vascular components of SSc. <h3>Disclosure of Interest</h3> C. Denton Grant/research support from: Inventiva, CSL Behring, GSK, Bayer, Consultant for: GSK, Actelion, Inventiva, Roche, Bayer, Boehringer Ingelheim, EMD Serono, Sanofi Aventis
Endemic Human Cutaneous Leishmaniasis Incidence in the United States—Reply
Authors: Bridget E. McIlwee
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials
Authors: Vincent Cottin, Arata Azuma, Ganesh Raghu, Wibke Stansen, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb
Journal: European Respiratory Journal (2019)

<b>In <i>post hoc</i> analyses of pooled data from the INPULSIS trials, the treatment effect of nintedanib <i>versus</i> placebo was not influenced by the presence of emphysema (yes <i>versus</i> no) or by FEV</b><sub><b>1</b></sub><b>/FVC ratio (≥0.7 to ≤0.8 <i>versus</i> &gt;0.8) at baseline</b>http://ow.ly/Gmwn30nwPY1